甘李药业股份有限公司股东及董事减持股份结果公告

Summary of Key Points Core Viewpoint - The announcement details the share reduction results of major shareholders and directors of Ganli Pharmaceutical Co., Ltd., indicating the completion of their planned share reductions and the specific amounts involved [1][2][3]. Group 1: Shareholder and Director Holdings - Before the reduction, Beijing Xute Hongda Technology Co., Ltd. and its concerted actor Mr. Gan Zhongru held a total of 241,116,992 shares, accounting for 40.11% of the company's total share capital [1]. - Among this, Xute Hongda held 35,473,235 shares (5.90%), while Mr. Gan Zhongru held 205,643,757 shares (34.21%) [1]. - Director Jiao Jiao held 270,000 shares, representing 0.045% of the total share capital [1]. Group 2: Implementation of Reduction Plans - On July 5, 2025, the company disclosed a share reduction plan where Xute Hongda intended to reduce up to 3,399,518 shares (0.57% of total share capital) through centralized bidding [2]. - Director Jiao Jiao planned to reduce up to 67,500 shares (0.0112% of total share capital) [2]. - From July 29 to August 14, 2025, Xute Hongda successfully reduced 3,399,501 shares (0.57% of total share capital), completing the reduction plan [2]. - Jiao Jiao reduced 67,500 shares from August 11 to August 14, 2025, also completing her reduction plan [2]. Group 3: Confirmation of Reduction Plan - The actual reduction matched the previously disclosed reduction plan, confirming that the reduction was fully implemented [3]. - The reduction was completed within the specified time frame, and there was no early termination of the reduction plan [3].